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Abnormal proplatelet formation 
and emperipolesis in cultured 
human megakaryocytes from gray 
platelet syndrome patients
Christian A. Di Buduo1,2, Maria Adele Alberelli3, Ana C. Glembostky4, Gianmarco Podda5, 
Paola R. Lev4, Marco Cattaneo5, Raffaele Landolfi3, Paula G. Heller4, Alessandra Balduini1,2,6 & 
Erica De Candia3
The Gray Platelet Syndrome (GPS) is a rare inherited bleeding disorder characterized by deficiency of 
platelet α-granules, macrothrombocytopenia and marrow fibrosis. The autosomal recessive form of 
GPS is linked to loss of function mutations in NBEAL2, which is predicted to regulate granule trafficking 
in megakaryocytes, the platelet progenitors. We report the first analysis of cultured megakaryocytes 
from GPS patients with NBEAL2 mutations. Megakaryocytes cultured from peripheral blood or bone 
marrow hematopoietic progenitor cells from four patients were used to investigate megakaryopoiesis, 
megakaryocyte morphology and platelet formation. In vitro differentiation of megakaryocytes was 
normal, whereas we observed deficiency of megakaryocyte α-granule proteins and emperipolesis. 
Importantly, we first demonstrated that platelet formation by GPS megakaryocytes was severely 
affected, a defect which might be the major cause of thrombocytopenia in patients. These results 
demonstrate that cultured megakaryocytes from GPS patients provide a valuable model to understand 
the pathogenesis of GPS in humans.
The gray platelet syndrome (GPS) is a rare inherited platelet disorder characterized by mild to moderate bleeding 
manifestations, thrombocytopenia, large platelets, increased serum B12 levels, spleen enlargement and progressive 
myelofibrosis1–3. The distinctive feature of the disease is the deficiency of platelet α -granules responsible for the 
typical gray appearance of platelets on Wright-stained blood smears1. Platelet α -granules store cargo proteins that 
mediate platelet adhesion (e.g. von Willebrand Factor), hemostasis (e.g. factor V), inflammation (e.g. IL-1β , IL-8, 
platelet factor 4) and wound healing and angiogenesis (e.g. VEGF, FGF-2, PDGF)4.
Although the GPS displays an autosomal recessive inheritance in most cases3, sporadic families with autoso-
mal dominant inheritance pattern have also been described5,6. Recently, by using a next generation sequencing 
approach, biallelic mutations in the neurobeachin-like 2 (NBEAL2) gene have been identified in autosomal reces-
sive forms of GPS7–9. NBEAL2 belongs to a family of proteins involved in the membrane dynamics and intracellu-
lar vesicle trafficking. One such protein, LYST, is mutated in Chediak-Higashi syndrome, which is characterized 
by defects in platelet granules and other lysosome-related organelles. The findings indicate that NBEAL2 may be 
critical for the development of platelet α -granules. However, the mechanisms by which NBEAL2 loss of function 
contributes to deficiency of platelet α -granules and their cargo proteins and to the macrothrombocytopenic state 
remain unknown.
Three different Nbeal2 deficient (−/−) mouse strains have been generated10–12. All of them recapitulate 
the typical platelet phenotype observed in GPS patients. Mice have macrothrombocytopenia, deficiency of 
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platelet α -granules and spleen enlargement. Myelofibrosis was demonstrated in older animals12. Nbeal2−/− 
mice were used to extensively study the role of platelet α -granules constituents in hemostasis, thrombosis, 
thrombo-inflammatory disease states, megakaryocyte survival and development, platelet production, tissue 
reconstitution after injury, development of myelofibrosis and cancer metastasis propagation. However, some dif-
ferences among the three Nbeal2−/− mouse strains were reported with regard to megakaryocyte development and 
differentiation, proplatelet formation and α -granules content. Therefore, whether Nbeal2 loss of function in mice 
affects megakaryopoiesis and/or proplatelet formation, and how it contributes to thrombocytopenia is unclear.
To investigate the impact of mutations in NBEAL2 gene on human thrombopoiesis, we enrolled four GPS 
patients, whose clinical features and NBEAL2 mutations have been previously described13–15. We obtained in vitro 
differentiated megakaryocytes from peripheral blood or bone marrow hematopoietic progenitor cells of the four 
GPS patients and five controls and evaluated megakaryocyte maturation and function and proplatelet formation.
Results
NBEAL2 mutations do not affect megakaryocyte differentiation by human hematopoietic pro-
genitors. We differentiated human megakaryocytes in vitro starting from peripheral blood or bone mar-
row hematopoietic progenitor cells of GPS patients with mutated NBEAL2 and healthy controls. Hereinafter, the 
patient carrying the c.1253del, c.3584G> A and c.5720+ 1G> A (r.5720_5721ins148) mutations will be identified 
as #1; the patient carrying the c.5572C> T, c.6652G> T and c.7033C> T mutations will be identified as #2; the 
two patients carrying the c.2187C> A homozygous mutations will be identified as #3 (Table 1). After 14 days of 
culture, in vitro megakaryocyte differentiation and output of CD61+CD42b+ megakaryocytes were similar to 
those of healthy control samples (Fig. 1a,b). Further, maturation stages of CD61+ megakaryocytes, classified I to 
IV according to standard morphological criteria16, were also similar in GPS patients and controls (Fig. 1c). No 
differences were observed among patients #1, #2 and #3, thus indicating that all the analyzed NBEAL2 mutations 
did not affect either the differentiation or the maturation of megakaryocytes. The results from both peripheral 
blood- and bone marrow-derived megakaryocytes were perfectively comparable (not shown).
Reduced α-granule content in human megakaryocytes from GPS patients. Despite normal 
differentiation, three of the most abundant proteins normally contained in α -granules, von Willebrand factor, 
thrombospondin and P-selectin, were markedly reduced in in vitro differentiated human megakaryocytes from 
both #1 and #2 GPS patients compared to controls (Fig. 2a–c). No differences were observed between patients, 
thus suggesting that the storage of these proteins was compromised in GPS megakaryocytes regardless of the 
type of mutation. Consistently, #1 and #2 GPS-derived megakaryocytes stimulated with protease activated recep-
tors (PARs)-activating peptides (APs) exposed less P-selectin compared to control megakaryocytes (Fig. 2d). 
Interestingly, these results are in agreement with those we have recently observed in platelets from peripheral 
blood of patients #1 and #215, and demonstrate that defective P-selectin mobilization is a distinctive feature that 
gray platelets inherit directly from their progenitors megakaryocytes before their release into bloodstream.
Evidence of emperipolesis in human megakaryocytes from GPS patients. Bone marrow mega-
karyocytes from gray platelets syndrome patients display intact cells within their cytoplasm, as a consequence of 
a rare biological process that is named emperipolesis6,15,17. Emperipolesis, present in less than 2% of megakaryo-
cytes in normal bone marrow biopsies, has been shown in 38% to 65% of megakaryocytes in GPS bone marrow 
biopsies15. However, whether this abnormality is directly dependent on NBEAL2 mutation rather than a conse-
quence of compromised bone marrow homeostasis, associated with the progressive myelofibrosis, has never been 
investigated. We found that several megakaryocytes from #1 and #2 GPS patients displayed the presence of intact 
cells within their cytoplasm, likely as a consequence of emperipolesis, while this abnormality was not observed in 
any of the mature megakaryocytes from control subjects (Fig. 3). The presence of cells other than megakaryocytes 
in our in vitro culture conditions is not surprising given the presence of a mixed population of cells in the culture 
media before megakaryocyte population is enriched through an albumin gradient18–21, which could grow and be 
engulfed within the megakaryocyte cytoplasm during the course of differentiation. To the best of our knowledge, 
none of the previously published studies of megakaryocytes from patients with other forms of thrombocytopenia 
or healthy subjects, grown under similar experimental conditions, revealed the presence of intact cells in cultured 
megakaryocytes20,22–24. Therefore, our study provides the first evidence that emperipolesis occurs in human GPS 
Patients cDNA (RNA for spicing mutations) Exon/Intron Protein Type of mutation Transmission
Patient 1 Rome (Italy)
c.1253del
#1
12 p.His418Leufs*54 Frameshift Maternal
c.3584G> A 25 p.Arg1195AGln Missense Paternal
c.5720+ 1G> A (r.5720_5721ins148) i35 p.Met1908* Splice-site Frameshift Paternal
Patient 2 Milan (Italy)
c.5572C> T
#2
34 p.Arg1858* Nonsense Paternal
c.6652G> T 41 p.Glu2218* Nonsense Paternal
c.7033C> T 45 p.Arg2345Trp Missense Maternal
Patients 3A and 
3B Buenos Aires 
(Argentina)**
c.2187C> A #3 16 p.Tyr729* Nonsense Maternal and Paternal
Table 1.  Mutations in NBEAL2 previously identified in three unrelated families and four probands. 
**Family from Buenos Aires had two affected brothers with homozygous NBEAL2 mutation. Clinical and 
laboratory features of the probands have been detailed elsewhere14.
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megakaryocytes as a consequence of an intrinsic cellular defect, rather than of abnormalities of the bone marrow 
microenvironment.
Calcium signaling is maintained in human megakaryocytes with mutated NBEAL2 gene. We 
have recently demonstrated that constitutively released adenosine diphosphate (ADP) by human mature mega-
karyocytes promotes the activation of Store-Operated Calcium Entry (SOCE) which in turn is responsible for the 
regulation of platelet formation and interaction with the components of the extracellular matrix19,25. We explored 
SOCE functionality in GPS megakaryocytes from #1 and #2 patients by depleting the stores with cyclopiazonic 
acid (CPA, 10 μM). The treatment evoked a transient rise in intracellular calcium (Ca2+) concentration, because of 
passive emptying of endoplasmic reticulum, followed by influx of external Ca2+ through activated SOC channels 
(Fig. 4a). Analysis of the extent of both Ca2+ release and entry demonstrated no significant difference between 
control- and GPS-derived megakaryocytes (Fig. 4b). Consistent with this data, megakaryocytes from #1 and #2 
GPS patients normally responded to ADP stimulation, with no significant differences in the extent of Ca2+ mobi-
lization compared to control megakaryocytes (Fig. 4c,d). All together, these data indicate that Ca2+ homeostasis 
is normally maintained in GPS megakaryocytes.
Human megakaryocytes from GPS patients show dramatically impaired proplatelet formation. 
An efficient Ca2+ signaling is fundamental in order to guarantee proper megakaryocyte interaction with extracel-
lular matrix components of the bone marrow environment25, which is in turn relevant for the control of  platelet 
release26,27. Therefore, based on the demonstration of a normal Ca2+ homeostasis in GPS  megakaryocytes, 
we expected that they could normally interact with extracellular matrix components. Surprisingly, the analy-
sis of GPS megakaryocyte interaction with type I collagen, an extracellular matrix component that promotes 
 megakaryocyte spreading by supporting cytoskeleton contractility27, revealed abnormal actin stress fibers for-
mation and microtubule assembly and, consequently, defective megakaryocyte spreading (Fig. 5). Similar results 
were observed in samples from #1 and #2 patients (Fig. 5v–xii). Further, the analysis of proplatelet formation on 
fibronectin28,29, revealed that megakaryocytes derived from either #1, #2 or #3 GPS patients displayed shorter 
proplatelet branches compared to control megakaryocytes (Fig. 6a). Similar results were obtained from both 
peripheral blood- (Fig. 6ai–vi,viii–xiii) and bone marrow-derived megakaryocytes (Fig. 6avii,xiv). The percentage 
of proplatelet forming megakaryocytes was markedly reduced in diseased megakaryocytes compared to controls, 
while no significant differences were observed among #1, #2 and #3 samples (Fig. 6b). The tips, terminal ends 
of proplatelet branches, are the site of the assembly of nascent platelets30. Consequently, the number of platelets 
that are formed depends on both the percentage of proplatelets and the number of their bifurcations in order to 
ensure the highest number of tips per single megakaryocyte. Proplatelets from GPS megakaryocytes displayed 
Figure 1. Normal differentiation of human megakaryocytes from patients with GPS. Hematopoietic 
progenitors from peripheral blood of healthy controls (CTRL) and patients with GPS were differentiated in 
culture into megakaryocytes in presence of TPO. (a) Representative immunofluorescence staining of plasma 
membrane CD61 in CTRL- (i) and GPS-derived megakaryocytes (ii–iv) (green = CD61; blue = nuclei; scale 
bar = 25 μm). (b) Statistical analysis of megakaryocyte (MK) output of GPS patients (#1, #2 and #3) relative 
to CTRL samples. Data are presented as mean ± SD (p = NS). (c) Statistical analysis of maturation stages in 
controls (CTRL)- and gray platelet syndrome patients- derived megakaryocytes (MK). Maturation stages were 
identified according to standard morphological criteria, as specified in the ‘Materials and Methods’ section. 
Data are presented as means ± SD of CTRL and all GPS patients GPS (p = NS). No differences were observed 
among patients.
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abnormal architecture with significant reduction in the absolute number of bifurcations compared to healthy con-
trols (Fig. 6c). These results were consistent with median platelet number of GPS patients, which was significantly 
lower in #1, #2 and #3 patients (56 × 103 platelets/μl, range: 30–65) than in healthy controls (294 × 103 platelets/
μl, range: 200–380). Moreover, we observed the presence of giant proplatelet tips and released platelets in cell cul-
tures from #1 and #2 GPS patients (Fig. 7), consistent with the findings that these patients displayed a significant 
macrothrombocytopenia (mean platelet volume: 3.9 μm, range: 3.5–4.3) with respect to healthy controls (mean 
Figure 2. Lack of α-granule proteins in GPS cultured megakaryocytes. Fully differentiated megakaryocytes 
from healthy controls (CTRL) and patients with GPS were harvested and allowed to adhere onto Poly-L-Lysine 
coated cover-slips by centrifugation, fixed and analyzed. (a) Representative immunofluorescence staining of von 
Willebrand Factor (vWF) in CTRL- (i–ii) and GPS-derived megakaryocytes (iii–iv) (red = vWF; blue = nuclei; 
scale bar = 20 μm). Bars report the analysis of fluorescence intensity by Image J software (a.u. = arbitrary 
units). Data are presented as mean± SD (*p < 0.05). (b) Representative immunofluorescence staining of 
thrombospondin in CTRL- (i–ii) and GPS-derived megakaryocytes (iii–iv) (green = thrombospondin; 
blue = nuclei; scale bar = 20 μm). Bars report the analysis of fluorescence intensity by Image J software 
(a.u. = arbitrary units). Data are presented as mean ± SD (*p < 0.05). (c) Representative immunofluorescence 
staining of P-selectin in CTRL- (i–ii) and GPS-derived megakaryocytes (iii–iv) (red = P-selectin; blue = nuclei; 
scale bar = 20 μm). Bars report the analysis of fluorescence intensity by Image J software (a.u. =  arbitrary 
units). Data are presented as mean± SD (*p < 0.05). (d) Representative flow cytometry analysis of P-Selectin 
exposure by CTRL- and GPS-derived megakaryocytes in basal condition (orange) and upon stimulation with 
25 μM PAR-1 and PAR-4 activating peptides (AP) (red). Bars highlight the increased percentage of P-Selectin+ 
megakaryocytes upon stimulation with respect to basal.
Figure 3. Emperipolesis in GPS cultured megakaryocytes: a distinctive feature of the disease is confirmed 
in in vitro model. (a) Representative hematoxylin and eosin staining of CTRL- (i–ii) and GPS-derived 
megakaryocytes (iii–vi). Arrows indicate intact cells that are going to and/or are already enclosed within 
megakaryocytes cytoplasm, thus indicating emperipolesis. (b) Percentage of emperipolesis in CTRL and GPS 
samples.
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platelet volume: 2.4 μm, range: 2–2.7). All together these data suggest that altered megakaryocyte interaction with 
extracellular environment, together with a severe defect in proplatelet formation and branching, may be the major 
causes of reduced platelet count and increased platelet size that characterize GPS.
Discussion
To the best of our knowledge, this the first report on megakaryopoiesis and proplatelet formation in cultured 
megakaryocytes from GPS patients carrying different autosomal recessive NBEAL2 mutations (Table 1). The 
observed results were, therefore, independent of the mutations or of their location to a particular domain of the 
gene.
Figure 4. Calcium dynamics are maintained in gray platelet syndrome megakaryocytes. (a) Intracellular 
calcium (Ca2+) pools were depleted by exposing megakaryocytes to cycolpiazonic acid (CPA, 10 μM) in Ca2+-
free (0Ca2+) solution. Re-addition of extracellular Ca2+ led to an increase in intracellular Ca2+ concentration 
which was indicative of activation of Store Operated Ca2+ Entry in both control (CTRL)- and #1 and #2 gray 
platelet syndrome (GPS)-derived megakaryocytes (red: CTRL; orange: #1 GPS; yellow: #2 GPS). (b) Statistical 
analysis of the peak amplitudes of both Ca2+ release and Ca2+ entry stimulated by CPA in CTRL- and #1and #2 
GPS-derived megakaryocytes. Data are presented as means± SD (p = NS). (c) Adenosine diphosphate (ADP, 
25 μM) evoked the activation of Ca2+ signaling in CTLR- and both #1 and #2 GPS-derived megakaryocytes 
(red: CTRL; orange: #1 GPS; yellow: #2 GPS). (d) Statistical evaluation of the effect of ADP treatment on the 
amplitudes of Ca2+ signaling in CTRL- and #1and #2 GPS-derived megakaryocytes. Data are presented as 
means± SD (p = NS).
Figure 5. Anomalous cytoskeleton contractility of GPS megakaryocytes upon adhesion on type I collagen. 
Control (CTRL)- (i–iv) and GPS-derived megakaryocytes (v–xii) at the end of differentiation were plated on 
type I collagen-coated cover-slips, at 37 °C in a 5% CO2 atmosphere. After 16 hours adherent cells were fixed 
and stained for immunofluorescence analysis of the cytoskeleton components actin (red = TRTIC-phalloidin) 
and tubulin (green = α -tubulin). Nuclei were counterstained with Hoechst 33258 in blue (scale bar = 20 μm).
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NBEAL2 mutations did not affect either the differentiation or the maturation of human megakaryocytes. 
Similar results were obtained in different patients, using different sources (peripheral blood and bone marrow) 
of hematopoietic progenitor cells to differentiate along the megakaryocytic lineage in culture. Our results are in 
Figure 6. Aberrant proplatelet formation by human megakaryocytes from patients with GPS.  
(a) Representative analysis of proplatelet formation and structure from control (CTRL)- (i–vii) and GPS-derived 
megakaryocytes by immunofluorescence (peripheral blood sample i–vi and viii–xiii; green = α -tubulin; 
red = CD61; blue = nuclei; scale bar = 50 μm) and light microscopy (bone marrow samples vii, xiv; scale 
bar = 20 μm). Pictures clearly show defective proplatelet elongation in GPS patients. (b) The percentage of 
proplatelet forming-megakaryocytes (ppf) was calculated as the number of megakaryocytes displaying at least one 
filamentous pseudopod with respect to total number of round megakaryocytes per analyzed field, and normalized 
with respect to CTRL. Data are presented as means ± SD (*p < 0.001). (c) Analysis of the number of proplatelet 
bifurcations per proplatelet forming-megakaryocytes (ppf). Data are presented as mean ± SD (*p < 0.001).
Figure 7. Giant proplatelet tips and released platelets from GPS megakaryocytes. Panel shows terminal 
proplatelet formation and platelet release by healthy controls (CTRL) (i) and GPS (ii,iii) megakaryocytes  
in vitro (green = α -tubulin; blue = nuclei; scale bar = 40 μm). Boxes highlight terminal proplatelet tips and 
platelet released in culture. Noteworthy, the size of both platelets tips and released platelets is markedly 
increased in GPS (vi,vii and viii,ix) than in CTRL (iv,v) samples (green = α -tubulin; scale bar = 20 μm).
www.nature.com/scientificreports/
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agreement with the clinical findings that, despite the presence of myelofibrosis, the number and the  maturation 
of megakaryocytes are not abnormal in patients with GPS2. Nbeal2−/− mouse models, to this regard, displayed 
different behaviors, which did not clarify the role of Nbeal2 in megakaryocyte differentiation10–12. In the bone 
marrow of Nbeal2−/− mice, compared to control mice, the megakaryocyte number was increased in one strain11, 
slightly increased in older mice in another strain and similar to control mice in the third one12. Cultured 
megakaryocytes from bone marrow revealed normal differentiation and number of high ploidy megakaryocytes 
in one model12 and reduced ploidy together with megakaryocytes arrested in the earliest stage of differentiation 
in another model10. Our findings in GPS patients show that NBEAL2 in humans does not affect the megakaryo-
poiesis, regardless of the type of mutations affecting the patients.
We also found a marked reduction of α -granule cargo and membrane proteins in mature megakaryocytes 
from #1 and #2 GPS patients compared to controls. These results are consistent with previous findings in the bone 
marrow biopsies of GPS patients15,31,32 and in the bone marrow of two Nbeal2−/− mouse models10,11. Moreover, 
they are in agreement with the demonstration that NBEAL2 is involved in the biogenesis/trafficking of granules 
in megakaryocytes7–9. Altogether these findings, although do not clarify whether the cause of reduced α -granule 
proteins is a hampered granule synthesis or a lack of retention of α -granules within the megakaryocytes, do 
confirm that the lack of α -granule proteins is present at the level of megakaryocytes (both culture-derived in 
vitro and in the bone marrow in vivo), and does not occur in platelets upon release of α -granules content into the 
circulation.
Emperipolesis was found in in vitro cultured GPS megakaryocytes from #1 and #2 patients. Emperipolesis, 
specifically the presence of leukocytes within the cytoplasm of megakaryocytes, has been already described as a 
prominent feature in bone marrow samples from GPS patients17, carrying both NBEAL215 and GFI1B mutations6, 
and in all three Nbeal2−/− mice10–12. These consistent findings suggest that this is a distinctive feature of GPS 
independent of the genotype and might be crucial for the development of the platelet phenotype. Our results 
on cultured megakaryocytes demonstrate that emperipolesis is intrinsic to these cells, independent of influence 
from microenvironment and/or other cells. Although the mechanism that favors emperipolesis in GPS is still 
far to be elucidated, some evidences suggest a mechanism similar to that described in primary myelofibrosis in 
humans, involving the mislocalization of P-selectin on megakaryocyte membrane favoring the interaction with 
leukocytes through the PSGL-1 countereceptor and their trapping within the megakaryocyte cytoplasm33,34. Also, 
a proinflammatory phenotype of Nbeal2−/− megakaryocytes overproducing and releasing chemoattractans has 
been hypothesized as the cause of this phenomenon12. Whatever the mechanism involved in this phenomenon, 
Guerrero et al. demonstrated that engulfment of cells within the megakaryocytes does not affect their survival 
and apoptosis12.
Ca2+ homeostasis was normal in #1 and #2 GPS megakaryocytes. Conversely, we report for the first time a 
dramatic defect in proplatelet formation and megakaryocyte interaction with extracellular matrix. GPS mega-
karyocytes, from all studied mutations and from both peripheral blood and bone marrow samples, displayed 
shorter proplatelet branches, a significant reduction in the absolute number of their bifurcations and abnormal 
architecture of proplatelets when compared to control megakaryocytes. Moreover, the percentage of proplatelet 
forming megakaryocytes was markedly reduced compared to controls, independently of genotype, in agreement 
with results obtained in Nbeal2−/− mice by Kahr et al.10. Unaltered proplatelet formation was reported in the other 
two Nbeal2−/− mouse models11,12. We also found altered GPS megakaryocyte interaction with type I collagen, a 
component of bone marrow extracellular matrix responsible for control of proper platelet formation through reg-
ulation of cytoskeleton contractility. It is well known that the release of cellular fibronectin, stored in α -granules, 
by mature megakaryocytes adhering on type I collagen is the major determinant for the maintenance of the tight 
interaction between cells and the substrates, which in turn favors the cytoskeleton contractility27. Thus, impaired 
α -granule assembly may be the cause for the altered megakaryocyte contractility in GPS patients.
Defective proplatelet formation together with altered megakaryocyte interaction with extracellular environ-
ment may be the major causes of congenitally reduced platelet count in patients with GPS. Other factors partially 
contributing the worsening of macrothrombocytopenia with age are splenomegaly and myelofibrosis. However, 
spleen removal causes a mild increase of the platelet count3, thus suggesting that splenomegaly is not the major 
cause of thrombocytopenia. Myelofibrosis is progressive in GPS and can account for the progressive reduction of 
platelet count as patients become older, but not for thrombocytopenia during childhood, when myelofibrosis can 
be absent3. By showing in vitro reduced proplatelet formation in cultured megakaryocytes from GPS patients, we 
provide a new mechanism for the thrombocytopenia in these patients.
In conclusion, this is the first systematic analysis of human, cultured GPS megakaryocytes and represents a 
comparator to the extensive work done with the Nbeal2−/− mice. Some differences and some similarities between 
NBEAL2 deficient megakaryocytes from GPS patients and Nbeal2 deficient megakaryocytes from mouse models 
are reported. We demonstrate that cultured human megakaryocytes from GPS patients with autosomal recessive 
mutation of NBEAL2 undergo normal differentiation and maturation and display, instead, severely impairment 
of both proplatelet formation and interaction with extracellular matrix. These two defects might be the major 
causes for the thrombocytopenia. We provide first evidence that emperipolesis, a distinctive feature of GPS, is a 
megakaryocyte-dependent phenomenon. Decreased content of α -granule proteins was found in cultured mega-
karyocytes, confirming that this phenomenon occurs at the level of megakaryocytes and not in circulating plate-
lets. Altogether these findings demonstrated that in vitro cultured megakaryocytes represent a valuable tool in 
understanding human GPS and it might of potential use to dissect the function of NBEAL2 at the molecular and 
cellular level to determine which trafficking steps are affected in the disease.
Materials and Methods
Materials. Adenosine 5′ -diphosphate (ADP), Hoechst 33258, Poly-L-lysine solution, paraformaldehyde 
(PFA), eosin-hematoxylin solution, Triton X-100, tetramethyrhodamine isothiocyanate (TRITC)-conjugated 
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phalloidin and cyclopiazonic acid from Penicillium cyclopium (CPA) were from Sigma Aldrich (Milan, Italy). 
Fura-2 acetoxymethyl ester (Fura-2 AM) was from Molecular Probes Europe BV (Leiden, The Netherlands). 
Human fibronectin was from BD Bioscience (Milan, Italy). Type I collagen was purified as described pre-
viously35. The following antibodies were used: monoclonal anti-CD61 (clone SZ21) (Immunotech, Marseille, 
France); goat monoclonal anti-CD61 (clone C-20) and mouse monoclonal anti-P-Selectin (clone 1E3) (Santa 
Cruz Biotechnology, California, USA); mouse monoclonal anti-α -tubulin (clone DM1A) and mouse mono-
clonal anti-human P-Selectin-allophycocyanin (APC) (clone clone AK4) (Sigma Aldrich, Milan, Italy); rabbit 
polyclonal anti-von Willebrand Factor (Dako, Milan, Italy); mouse monoclonal anti-Thrombospondin (clone 
A6.1), mouse monoclonal anti-CD61-fluorescein isothiocyanate (FITC) (clone PM6/13) and mouse monoclonal 
anti-CD42b-phycoerythrin (PE) (clone HIP1) (Abcam, Cambridge, UK); anti-CD61-FITC and anti-CD42b-PE 
(BD Biosciences, San José, CA, USA); Alexa Fluor-conjugated antibodies (Invitrogen, Milan, Italy).
Solutions. Physiological salt solution (PSS) had the following composition: NaCl 150 mM, KCl 6 mM, CaCl2 
1.5 mM, MgCl2 1 mM, glucose 10 mM, Hepes 10 mM. In Ca2+-free solution (0Ca2+), Ca2+ was substituted with 
NaCl 2 mM and EGTA 0.5 mM was added. Solutions were titrated to pH 7.4 with NaOH.
Patients. Clinical and genetic features of patients 1 and 2, from Italy and of patients 3A and 3B (brothers), 
from Argentina, have been already reported13–15. Briefly, at the time of this study patients 1, 2, 3A and 3B were, 
respectively, 23, 8, 68 and 73 year-old. All patients had similar degree of macrothrombocytopenia, as reported in 
the result section, whereas leukocyte and red blood cells counts were not affected. All the details regarding the 
type of NBEAL2 mutations are reported in Table 1.
Blood (all patients) and bone marrow (patient 3A) samples were obtained with informed consent of the 
patients or of the parents in case of minor age. Four healthy volunteers were recruited as controls for periph-
eral blood samples. Bone marrow sample from one patient with Ewing sarcoma, who underwent bone marrow 
biopsy for staging of the disease and without bone marrow involvement, was used as a control for bone marrow 
sample. Cultures of peripheral blood and of bone marrow samples of patients and controls were run in parallel 
in each experiment. The study was performed in accordance with the principles of the Declaration of Helsinki. 
The study was approved by the ethical committees of Policlinico Agostino Gemelli, Rome, Italy and of Instituto 
de Investigaciones Médicas Alfredo Lanari, CONICET, Buenos Aires, Argentina, involved in the management of 
enrolled patients.
Differentiation of human megakaryocytes and morphological analysis. CD45+ from peripheral 
blood or CD34+ from bone marrow samples were separated by immunomagnetic bead selection (Miltenyi Biotec, 
Bologna, Italy) and cultured in Stem Span medium supplemented with 10 ng/mL thrombopoietin (TPO), inter-
leukin (IL)-6 and IL-11 at 37 °C in a 5% CO2 fully humidified atmosphere, as previously described18,20,22. At the 
end of the culture (14th day) 150 × 103 cells were collected, cytospun on glass coverslips and stained with a pri-
mary antibody against CD61 (1:100) to evaluate megakaryocyte differentiation. Nuclei were stained with Hoechst 
33258 (1:10000). CD61+ megakaryocytes were assigned to distinct stages of maturity according to standard mor-
phological criteria16, as previously described20,21,36. Specifically, in the early maturation stage (I) megakaryocytes 
present the lowest cytoplasmic/nuclear ratio, compact nucleus and small size. Successive stages (II, III) are iden-
tified by progressive cytoplasmic mass increase and highly lobulated nuclei. Fully differentiated megakaryocytes 
(stage IV) present the highest cytoplasmic/nuclear ratio. For each specimen, at least 100 megakaryocytes were 
evaluated.
For the analysis of the α -granules content, at day 14 of the culture megakaryocytes were harvested, seeded 
onto glass coverslips, previously coated with Poly-L-Lysine, and allowed to adhere by centrifugation at 240 × g. 
Cells were then fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and stained with anti-von 
Willebrand Factor (1:100), anti-thrombospondin (1:50) or anti–P-Selectin (1:100). Nuclei were stained with 
Hoechst 33258 (1:10000). The fluorescence intensity was quantified by Image J software. Values are reported as 
arbiter units (a.u.). For each specimen, at least 100 megakaryocytes were evaluated.
For the analysis of emperipolesis, after fixation, samples were stained with hematoxylin and eosin. For each 
specimen, at least 200 megakaryocytes were evaluated. Results are expressed as percentage of total cells analyzed.
For all experiments the coverslips were mounted onto glass slides with ProLong Gold antifade reagent 
(Invitrogen, Milan, Italy) and images acquired by Olympus BX51 microscope (Olympus, Deutschland GmbH, 
Hamburg, Germany).
Flow cytometry analysis. 200 × 103 cells were collected at the end of the culture (14th day) and centri-
fuged at 250xg for 7 minutes. Cells were then suspended in phosphate buffer saline (PBS) and stained with a 
FITC-conjugated antibody against human CD61 and a PE-conjugated antibody against human CD42b, at room 
temperature, in the dark for 30 minutes. The number of CD61+CD42b+ megakaryocytes (megakaryocyte output) 
from GPS patients was calculated and evaluated with respect to those of healthy controls.
For analysis of P-Selectin exposure samples were stimulated with 25 μM of both PAR-1 and PAR-4 activat-
ing peptides for 20 minutes, at 37 °C, in presence of 2 μM CaCl2 and 2 μM MgCl2. Cells were then stained with 
APC-conjugated antibody against human P-Selectin antibody for additional 15 minutes. In all described exper-
iments, after incubation, samples were immediately analyzed by a Beckman Coulter Navios flow cytometer. 
Non-stained samples were used to set the correct analytical gating. Off-line data analysis was performed using 
Beckman Coulter Navios software package.
Evaluation of cell adhesion and proplatelet formation on fibronectin and type I collagen. In 
order to analyze megakaryocyte adhesion and proplatelet formation onto different extracellular matrix 
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components, 12 mm glass cover-slips were coated with 25 μg/ml fibronectin or 25 μg/ml type I collagen, over-
night at 4 °C, as previously described. At the end of the culture megakaryocyte population was enriched through 
a BSA gradient as previously described20. 1 × 105 megakaryocytes were harvested and allowed to adhere at 37 °C 
and 5% CO2. After 16 hours, adhering cells were visualized either by phase contrast images by an Olympus IX53 
microscope (Olympus, Deutschland GmbH, Hamburg, Germany) or fixed in 4% PFA, permeabilized with 0.1% 
Triton X-100, and stained for immunofluorescence evaluation by an Olympus BX51 microscope (Olympus, 
Deutschland GmbH, Hamburg, Germany). Briefly, for immunofluorescence staining samples were stained 
with anti-α -tubulin antibody (1:700), TRITC-conjugated phalloidin (1:5000) and/or CD61 (1:100), as previ-
ously described25,27. Nuclei were stained with Hoechst 33258 (1:10000). The cover-slips were mounted onto glass 
slides with ProLong Gold antifade reagent (Invitrogen, Milan, Italy). At least 50 fields per sample were analyzed. 
Cytoskeleton reorganization was recognized in cells displaying microtubule and stress fibers assembly. Proplatelet 
forming-megakaryocytes were identified as cells displaying long filamentous structure ending with platelet-sized 
tips. The percentage of proplatelets from GPS patients was compared with respect to those of healthy controls.
Measurements of intracellular calcium concentration. The analysis of Ca2+ flows was performed as 
previously described25,37. 12 mm glass coverslips were coated with 25 μg/ml fibronectin, overnight at 4 °C. Mature 
megakaryocytes were plated onto substrate-coated cover-slips in 24-wells plates (1 × 105 cells/well). After 60 min-
utes at 37 °C and 5% CO2, megakaryocytes were loaded with 4 μM fura-2 AM in PSS. After 30 minutes, the cover-
slip was fixed to the bottom of a Petri dish and the cells were observed using an upright epifluorescence Axiolab 
microscope (Carl Zeiss). Custom software, working in the LINUX environment, was used to drive the camera 
(Extended-ISIS Camera; Photonic Science) and the filter wheel and to measure and plot on-line the fluorescence 
from single cells enclosed in rectangular regions of interest (ROI). Intracellular Ca2+ concentration ([Ca2+]i) was 
monitored by measuring, for each ROI, the ratio of the mean fluorescence emitted at 510 nm when exciting alter-
natively at 340 and 380 nm (shortly termed “RATIO”). An increase in [Ca2+]i causes an increase in the ratio. The 
experiments were performed at room temperature.
Statistic. Megakaryocyte cultures were performed three times from peripheral blood of patient 1, two times 
from peripheral blood of patient 2, two times from peripheral blood and one time from bone marrow of patient 
3A, one time from peripheral blood of patient 3B and each experiment was independently replicated at least 3 
times, unless specified otherwise. Control samples from healthy volunteers (peripheral blood samples) and from 
one patient with Ewing sarcoma and no bone marrow involvement (bone marrow sample) were always performed 
in parallel. For all the experiments values are expressed as mean ± SD of all independent experiments. Student’s 
t-test was performed for statistical analysis. Values of at least p < 0.05 were considered statistically significant.
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